Search

Autologous antigen-specific therapies based on tolerogenic dendritic cells (tolDC) offer the possibility to treat autoimmune diseases by restoring homeostasis and targeting specifically autoreactive responses. Here, we explore the hypothesis that systemic inflammation occurring in autoimmune diseases, such as multiple sclerosis (MS), can generate a disease-specific environment able to alter the functionality of tolDC. In this context in fact, a combined therapy of tolDC with an immunomodulatory treatment could potentiate the beneficial effect of this antigen-specific cell therapy. For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS. VitD3-tolDC were generated from healthy donors and MS patients and co-cultured with allogeneic peripheral blood mononuclear cells, in the presence or absence of IFN-beta. In vitro, VitD3-tolDC treatment reduced the percentage of activated T cells and allogeneic proliferation, whereas VitD3-tolDC+IFN-beta treatment enhanced the suppressive ability of VitD3-tolDC and, additionally, induced a shift towards a Th2 profile. To determine the clinical benefit of the combined therapy, C57BL/6-experimental autoimmune encephalomyelitis (EAE)-induced mice were treated with antigen-specific VitD3-tolDC and/or IFN-beta. Treatment of EAE mice with combined therapy ameliorated the disease course compared to each monotherapy. These results suggest that a combined therapy based on antigen-specific VitD3-tolDC and IFN-beta may represent a promising strategy for MS patients.

Dendritic cells (DC) are responsible for the initiation and shaping of the adaptive immune response and are in the focus of autoimmunity research. We were interested in comparison of DC obtained from autoimmunity-prone Dark Agouti (DA) rats and autoimmunity-resistant Albino Oxford (AO) rats. DC were generated from bone marrow precursors and matured (mDC) by lipopolysaccharide. Tolerogenic DC (tolDC) obtained by vitamin D3 treatment were studied in parallel. Profile of cytokine production was different in AO and DA mDC and tolDC. Expression of MHC class II molecules and CD86 were higher in DA DC, while vitamin D3 reduced their expression in dendritic cells of both strains. Allogeneic proliferation of CD4+ T cells was reduced by AO tolDC, but not with DA tolDC in comparison to respective mDC. Finally, expression of various genes identified as differentially expressed in human mDC and tolDC was also analyzed in AO and DA DC. Again, AO and DA DC differed in the expression of the analyzed genes. To conclude, AO and DA DC differ in production of cytokines, expression of antigen presentation-related molecules and in regulation of CD4+ T proliferation. The difference is valuable for understanding the divergence of the strains in their susceptibility to autoimmunity.

mRNA-based vaccines effectively induce protective neutralizing antibody responses against SARS-CoV-2, the etiological agent of COVID-19. The specific compositional patterns of these responses remain largely unknown. We found that SARS-CoV-2-naïve individuals receiving the first dose of an mRNA vaccine developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by the natural infection, except IgA2, which did not increase. SARS-CoV-2-naïve subjects also mounted a robust virus-specific recall response after receiving the second dose. This response increased all IgG subclasses, but boosted neither IgM nor IgA1 and IgA2 subclasses. In contrast, individuals recovered from COVID-19 mounted peak virus-specific antibody responses upon primary immunization and did not further augment such responses following secondary immunization. Remarkably, compared to SARS-CoV-2-naïve subjects, individuals with pre-existing immunity showed increased levels of all virus-specific antibodies but IgG3 following primary vaccination. By dissecting the heterogeneity of mRNA vaccine-induced humoral responses to SARS-CoV-2, our findings indicate that the induction of optimal immune protection may require the development of personalized vaccination programs.

Background In natalizumab-treated relapsing-remitting MS (RRMS) patients, various extended interval dosing strategies are under evaluation to minimize severe treatment-associated side effects, mainly progressive multifocal leukoencephalopathy development. Up to now, it has not been presented any approach, even in form of assay design, to determine the optimal percentage of CD49d receptor occupancy (RO) associated with a favorable clinical, radiological, and immunological response. Methods A multiparametric quantitative flow cytometry method was settled to measure CD49d RO on peripheral blood lymphocytes. The analytical protocol was tested in a 6-month follow-up from 19 RRMS patients treated with the natalizumab standard dosing of every 4 weeks or an extended-interval dosing of every 6 weeks. Results Extended natalizumab dose schedule promoted an increase of CD49d molecules per cell surface and a reduction of CD49d RO levels. The reduction observed on CD49d RO was not only depending on dose schedule but also on individual parameters such as body mass. Interestingly, individual clinical outcome was apparently the same between the different dose schedules or even better with the extended interval dosing. Conclusions Following up CD49d RO levels with a well-regulated monitoring work scheme is crucial to further identify over-/under-treated patients and to define a safe, personalized natalizumab regimen. © 2017 International Clinical Cytometry Society

Background: Although effective in reducing relapse rate and delaying progression, current therapies for multiple sclerosis (MS) do not completely halt disease progression. T cell autoimmunity to myelin antigens is considered one of the main mechanisms driving MS. It is characterized by autoreactivity to disease-initiating myelin antigen epitope(s), followed by a cascade of epitope spreading, which are both strongly patient-dependent. Targeting a variety of MSassociated antigens by myelin antigen-presenting tolerogenic dendritic cells (tolDC) is a promising treatment strategy to re-establish tolerance in MS. Electroporation with mRNA encoding myelin proteins is an innovative technique to load tolDC with the full spectrum of naturally processed myelin-derived epitopes. Methods: In this study, we generated murine tolDC presenting myelin oligodendrocyte glycoprotein (MOG) using mRNA electroporation and we assessed the efficacy of MOG mRNA-electroporated tolDC to dampen pathogenic T cell responses in experimental autoimmune encephalomyelitis (EAE). For this, MOG35–55- immunized C57BL/6 mice were injected intravenously at days 13, 17, and 21 post-disease induction with 1α, 25-dihydroxyvitamin D3-treated tolDC electroporated with MOG-encoding mRNA. Mice were scored daily for signs of paralysis. At day 25, myelin reactivity was evaluated following restimulation of splenocytes with myelin-derived epitopes. Ex vivo magnetic resonance imaging (MRI) was performed to assess spinal cord inflammatory lesion load.Results: Treatment of MOG35–55-immunized C57BL/6 mice with MOG mRNA-electroporated or MOG35–55- pulsed tolDC led to a stabilization of the EAE clinical score from the first administration onwards, whereas it worsened in mice treated with non-antigen-loaded tolDC or with vehicle only. In addition, MOG35–55-specific pro-inflammatory pathogenic T cell responses and myelin antigen epitope spreading were inhibited in the peripheral immune system of tolDC-treated mice. Finally, magnetic resonance imaging analysis of hyperintense spots along the spinal cord was in line with the clinical score. Conclusions: Electroporation with mRNA is an efficient and versatile tool to generate myelin-presenting tolDC that are capable to stabilize the clinical score in EAE. These results pave the way for further research into mRNA-electroporated tolDC treatment as a patient-tailored therapy for MS. This work was supported by the Methusalem Funding Program from the University of Antwerp, by an applied biomedical research project of the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWTTBM 140191), and by the Belgian Charcot Foundation. Furthermore, the authors received research funding from Roche Belgium. Judith Derdelinckx holds a PhD fellowship from the Research Foundation Flanders (FWO)

Aim Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing‐remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. The objective of this study was to identify early biomarkers of treatment response by analyzing changes in peripheral leukocyte subpopulations directly in whole blood samples. Methods A longitudinal and prospective study analyzing peripheral blood leukocyte subpopulations in 22 RRMS patients before initiating DMF treatment (baseline) and at 1, 3, 6, and 12 months of follow‐up was performed. Differences between no evidence of disease activity (NEDA) and ongoing disease activity (ODA) patients were analyzed. Results The beneficial effect of DMF was associated with a specific depletion of memory CD4+ and CD8+ T lymphocytes and B cells. Importantly, only NEDA patients showed (a) a shift from a pro‐ to an antiinflammatory profile, with an increase of Th2 cells and a decrease of Th1‐like Th17 lymphocytes; and (b) an increase of regulatory CD56bright NK cells. Conclusion The optimal response to DMF is mediated by a shift to antiinflammatory and immunoregulatory profile, which puts forward Th1‐like Th17 lymphocytes as a potential early biomarker of treatment response.

The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. In this article, we generated human vitD3-tolDC from monocytes from healthy donors and MS patients, characterized in both cases by a semi-mature phenotype, secretion of IL-10 and inhibition of allogeneic lymphocyte proliferation. Additionally, we studied their transcriptomic profile and selected a number of differentially expressed genes compared to control mature and immature dendritic cells for their analysis. Among them, qPCR results validated CYP24A1, MAP7 and MUCL1 genes as biomarkers of vitD3-tolDC in both healthy donors and MS patients. Furthermore, we constructed a network of protein interactions based on the literature, which manifested that MAP7 and MUCL1 genes are both closely connected between them and involved in immune-related functions. In conclusion, this study evidences that MAP7 and MUCL1 constitute robust and potentially functional biomarkers of the generation of vitD3-tolDC, opening the window for their use as quality controls in clinical trials for MS.

Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n=22) or fingolimod (n=44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11.60±4.17%vs. nonrelapsed: 9.25±3.17%, p<0.05) and Th1Th17CM cells (relapsed: 15.65±6.15%vs. nonrelapsed: 10.14±4.05%, p<0.01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells>11.48% had a 50% relapse-free survival compared to patients with Th1Th17CMcells<11.48% whose relapse-free survival was 88% (p=0.013, log-rank test). Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14.02±5.87%vs. no MRI activity: 9.82±4.06%, p<0.01). Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.

The last years have witnessed a breakthrough in the development of cell-based tolerance-inducing cell therapies for the treatment of autoimmune diseases and solid-organ transplantation. Indeed, the use of tolerogenic dendritic cells (tolDC) and regulatory macrophages (Mreg) is currently being tested in Phase I and Phase II clinical trials worldwide, with the aim of finding an effective therapy able to abrogate the inflammatory processes causing these pathologies without compromising the protective immunity of the patients. However, there exists a wide variety of different protocols to generate human tolDC and Mreg and, consequently, the characteristics of each product are heterogeneous. For this reason, the identification of biomarkers able to define their functionality (tolerogenicity) is of great relevance, on the one hand, to guarantee the safety of tolDC and Mreg before administration and, on the other hand, to compare the results between different cell products and laboratories. In this article, we perform an exhaustive review of protocols generating human tolDC and Mreg in the literature, aiming to elucidate if there are any common transcriptomic signature or potential biomarkers of tolerogenicity among the different approaches. However, and although several effectors seem to be induced in common in some of the most reported protocols to generate both tolDC or Mreg, the transcriptomic profile of these cellular products strongly varies depending on the approach used to generate them.

Aims Fingolimod, an orally active immunomodulatory drug for relapsing-remitting multiple sclerosis (RRMS), sequesters T cells in lymph nodes through functional antagonism of the sphingosine-1-phosphate receptor, reducing the number of potential autoreactive cells that migrate to the central nervous system. However, not all RRMS patients respond to this therapy. Our aim was to test the hypothesis that by immune-monitoring RRMS patient's leukocyte subpopulations it is possible to find biomarkers associated with clinical response to fingolimod. Methods Results Prospective study. Analysis of peripheral blood mononuclear cell subpopulations by multiparametric flow cytometry, at baseline and +1, +3, +6, +12 months of follow-up in 40 RRMS patients starting fingolimod therapy. Fingolimod treatment induced a severe lymphopenia affecting mainly T and B cells. A relative increase in T-reg (memory T-reg: 3.8 +/- 1.0% baseline vs 8.8 +/- 4.4% month +1; activated T-reg: 1.5 +/- 0.7% baseline vs 3.7 +/- 2.1% month +1, P < 0.001) as well as transitional B cells (10.5 +/- 12.3% baseline vs 18.7 +/- 14.6% month +1, P < 0.001) was observed. Interestingly, lymphocyte subpopulations were already at baseline significantly different in responder patients. The percentage of recent thymic emigrants (RTE) used to stratify fingolimod responder, and no responder patients was the best biomarker (4.0 +/- 1.4% vs 7.4 +/- 1.9%, respectively [P < 0.001]). Conclusion The results support that immune-monitoring of lymphocyte subpopulations in peripheral blood is a promising tool to select RRMS candidate for fingolimod treatment.

et al., [Aim]: Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. [Materials & methods]: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. [Results]: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. [Conclusion]: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application., This work was supported by a grant from the Spanish Government (FIS PI15/00198) co-financed with the European Regional Development funds (FEDER) and by CERCA Programme, Generalitat de Catalunya. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) is an initiative from Instituto de Salud Carlos III. This work has been supported by positive discussion through A FACTT network (Cost Action BM1305: www.afactt.eu). COST is supported by the EU Framework Programme Horizon 2020. S Rodriguez-Fernandez and J Navarro-Barriuso are supported by grants from the AGAUR, Generalitat de Catalunya.

Summary Background Treatment with tolerogenic dendritic cells (TolDC) is a promising, cell-based strategy to regulate autoimmune diseases such as multiple sclerosis (MS) in an antigen-specific way. This technique involves the use of TolDC from MS patients cultured in the presence of vitamin D3 (VitD3) and pulsed with myelin peptides to induce a stable hyporesponsiveness in myelin-specific autologous T cells. Aim The purpose of this study was to analyze the in vivo effect of VitD3-TolDC treatment on experimental autoimmune encephalomyelitis, an animal model of MS. Methods Bone marrow-derived TolDC cultured in the presence of VitD3 and pulsed with peptide 40–55 of the myelin oligodendrocyte glycoprotein (MOG40–55) were administrated preventively, preclinically, and therapeutically to EAE-induced mice. Results We found that VitD3-TolDC-MOG treatment showed a beneficial effect, not only decreasing the incidence of the disease but also reducing the severity of the clinical signs mediated by induction of regulatory T cells (Treg), as well as IL-10 production and reduction of Ag-specific lymphoproliferation. Our results support VitD3-TolDC-peptide(s) treatment as a potential strategy to restore tolerance in autoimmune diseases such as MS.

The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. However, the mechanisms that vitD3-tolDC trigger for the induction of tolerance remain elusive. For this reason, we performed a full phenotypical, functional, and transcriptomic characterization of T cells upon their interaction with autologous, antigen-specific vitD3-tolDC. We observed a strong antigen-specific reduction of T cell proliferation, combined with a decrease in the relative prevalence of T1 subpopulations and IFN- γ production. The analysis of the transcriptomic profile of T CD4 + cells evidenced a significant down-modulation of genes involved in cell cycle and cell response to mainly pro-inflammatory immune-related stimuli, highlighting the role of JUNB gene as a potential biomarker of these processes. Consequently, our results show the induction of a strong antigen-specific hyporesponsiveness combined with a reduction on the T1 immune profile of T cells upon their interaction with vitD3-tolDC, which manifests the regulatory properties of these cells and, therefore, their therapeutic potential in the clinic. https://doi.org/10.13039/5011000033295https://doi.org/10.13039/5011000033293https://doi.org/10.13039/5011000033296https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329_https://doi.org/10.13039/501100003329_https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329 $h ttps://doi.org/10.13039/501100003329fhttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329Phttps://doi.org/10.13039/501100003329Ihttps://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033294https://doi.org/10.13039/501100003329/https://doi.org/10.13039/5011000033290https://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033297https://doi.org/10.13039/5011000033295https://doi.org/10.13039/501100003329 https://doi.org/10.13039/5011000033295https://doi.org/10.13039/5011000033293https://doi.org/10.13039/5011000033296https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329_https://doi.org/10.13039/501100003329_https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329 $h ttps://doi.org/10.13039/501100003329ahttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329Mhttps://doi.org/10.13039/501100003329ihttps://doi.org/10.13039/501100003329nhttps://doi.org/10.13039/501100003329ihttps://doi.org/10.13039/501100003329shttps://doi.org/10.13039/501100003329thttps://doi.org/10.13039/501100003329ehttps://doi.org/10.13039/501100003329rhttps://doi.org/10.13039/501100003329ihttps://doi.org/10.13039/501100003329ohttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329dhttps://doi.org/10.13039/501100003329ehttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329Ehttps://doi.org/10.13039/501100003329chttps://doi.org/10.13039/501100003329ohttps://doi.org/10.13039/501100003329nhttps://doi.org/10.13039/501100003329ohttps://doi.org/10.13039/501100003329mhttps://doi.org/10.13039/501100003329íhttps://doi.org/10.13039/501100003329ahttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329yhttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329Chttps://doi.org/10.13039/501100003329ohttps://doi.org/10.13039/501100003329mhttps://doi.org/10.13039/501100003329phttps://doi.org/10.13039/501100003329ehttps://doi.org/10.13039/501100003329thttps://doi.org/10.13039/501100003329ihttps://doi.org/10.13039/501100003329thttps://doi.org/10.13039/501100003329ihttps://doi.org/10.13039/501100003329vhttps://doi.org/10.13039/501100003329ihttps://doi.org/10.13039/501100003329dhttps://doi.org/10.13039/501100003329ahttps://doi.org/10.13039/501100003329dhttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329 $h ttps://doi.org/10.13039/501100000780ahttps://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780Ehttps://doi.org/10.13039/501100000780uhttps://doi.org/10.13039/501100000780rhttps://doi.org/10.13039/501100000780ohttps://doi.org/10.13039/501100000780phttps://doi.org/10.13039/501100000780ehttps://doi.org/10.13039/501100000780ahttps://doi.org/10.13039/501100000780nhttps://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780Chttps://doi.org/10.13039/501100000780ohttps://doi.org/10.13039/501100000780mhttps://doi.org/10.13039/501100000780mhttps://doi.org/10.13039/501100000780ihttps://doi.org/10.13039/501100000780shttps://doi.org/10.13039/501100000780shttps://doi.org/10.13039/501100000780ihttps://doi.org/10.13039/501100000780ohttps://doi.org/10.13039/501100000780nhttps://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780 $h ttps://doi.org/10.13039/501100003329dhttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329 $h ttps://doi.org/10.13039/501100000780fhttps://doi.org/10.13039/501100000780 https://doi.org/10.13039/5011000007807https://doi.org/10.13039/5011000007807https://doi.org/10.13039/5011000007809https://doi.org/10.13039/5011000007803https://doi.org/10.13039/5011000007801https://doi.org/10.13039/5011000007806https://doi.org/10.13039/501100000780 $h ttps://doi.org/10.13039/501100000780dhttps://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780 $h ttps://doi.org/10.13039/501100003329fhttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329Phttps://doi.org/10.13039/501100003329Ihttps://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033294https://doi.org/10.13039/501100003329/https://doi.org/10.13039/5011000033290https://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033297https://doi.org/10.13039/5011000033293https://doi.org/10.13039/5011000033297https://doi.org/10.13039/501100003329 https://doi.org/10.13039/5011000033295https://doi.org/10.13039/5011000033293https://doi.org/10.13039/5011000033296https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329_https://doi.org/10.13039/501100003329_https://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329 $h ttps://doi.org/10.13039/501100003329fhttps://doi.org/10.13039/501100003329 https://doi.org/10.13039/501100003329Phttps://doi.org/10.13039/501100003329Ihttps://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033294https://doi.org/10.13039/501100003329/https://doi.org/10.13039/5011000033290https://doi.org/10.13039/5011000033291https://doi.org/10.13039/5011000033295https://doi.org/10.13039/5011000033292https://doi.org/10.13039/5011000033291https://doi.org/10.13039/501100003329 https://doi.org/10.13039/5011000007805https://doi.org/10.13039/5011000007803https://doi.org/10.13039/5011000007806https://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780_https://doi.org/10.13039/501100000780_https://doi.org/10.13039/501100000780 https://doi.org/10.13039/501100000780